Indication expansion

A year in Longevity: different perspectives

Looking for anti-aging solutions in some unusual places. 2020 has seen Longevity.Technology covering a variety of news in the Longevity sector, from discoveries in the...

Longevity biomarker firm to align CROs, pharma and consumers

Cerascreen expands from consumer biomarker testing into clinical trial recruitment and discovery of Longevity compounds. Combining a wide range of consumer biomarker testing kits with...

Eliminating senescent cells to improve heart attack recovery

A drug that exterminates senescent cells improves recovery after a heart attack, according to new research, and could pave the way for a new...

Calico’s memory-enhancing drug reverses age-related mental decline

UCSF study shows Calico-licensed small molecule cognitive enhancer ISRIB reverses age-related memory decline in mice within days. ISRIB (integrated stress response inhibitor) is an experimental...

BioAge CEO: “It’s all about the data.”

BioAge's Kristen Fortney explains how focusing on human data will see two age-targeting drugs head to the clinic next year. Yesterday, the world again sat...

BioAge lands $90 million; gears up for clinical trials in 2021

Company also appoints Chief Medical Officer as it prepares to enter the clinic with two Phase 2-ready therapeutic compounds that target aging pathways. Longevity biotech...

AgelessRx and funding an IRB-approved rapamycin trial

Rapamycin could be the PEARL in the Longevity oyster as new human trial seeks funding. AgelessRx is a platform that sells drugs and supplements including...

Inflammaging – could ibuprofen be the answer?

Neurodegenerative disease is associated with age-related chronic, low grade inflammation, but studies suggest that this could be reversed with over the counter NSAIDs. In an...

Peptide molecule causes cancer cells to self destruct

New breakthrough by a team led by eminent oncologist Loren Walensky brings new hope for future cancer treatments – and Longevity.  Everyone needs a way...

Using small data to target Alzheimer’s

NetraMark CEO on using AI to identify novel targets for treatment of Alzheimer’s disease. Despite the billions spent on research and development into treatments for...

Combining existing medicines to target aging

Rejuvenate Biomed closes in on €9 million funding round for human trials of sarcopenia-targeted combined drug. Already well-known for its beer and bureaucracy to its...

Reproductive Longevity – taking the geroscience approach

Applying geroscience interventions to fertility pathways can promote reproductive Longevity. Dr Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge...

Longevity-extending compounds key to neurodegenerative treatment

Compounds found to increase lifespan in animal models could hold the key to treatments for debilitating neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.  Neurodegenerative...

The metformin debate swings both ways

Research on metformin is not at the beginning of the end, but it is, perhaps, at the end of the beginning. The drug giveth and...

$2m Longevity boost for rapamycin Alzheimer’s study

Rapamycin human clinical trial aims to make progress on Alzheimer's therapy. A new $2m grant will enable a clinical trial to examine the effects of...

GlobalData finds AI accelerates drug repurposing

GlobalData says AI holds significant promise for biopharmaceutical companies to expedite the drug repurposing process. Artificial intelligence is the go-to engine for research breakthroughs. Applying...

FDA approval for small molecule drug bodes well for Longevity

Roche, the world’s largest biotech company, has won approval from the FDA for an SMA drug. The race to take a therapy from lab to...

Fruit fly research could hold key to lifespan

Research carried out on the effects of the drug Mifepristone on fruit flies and roundworms has revealed key findings that could pave the way...

Exploring the neuroprotective benefits of Longevity drug candidates

Understanding the role aging plays in neurodegenerative diseases could be the key to curing them – or even preventing them with neuroprotective candidates. A team...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...
ChromaDex TruNiagen
whoop

Latest articles